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Background:  Little is known about the efficacy of `-blocker therapy after complete revascularization by percutaneous coronary intervention (PCI) 
in patients with stable angina pectoris (SAP) and left ventricular (LV) dysfunction.
Methods:  A total of 816 consecutive patients SAP received PCI, and had no restenosis at 6-8 months follow-up coronary angiography were enrolled 
in this study. We divided into 4 groups according to the ejection fraction (EF) on left ventriculography (LVG) before PCI and to the prescription of 
`-blocker after PCI; group A: EF <50% with `-blocker (n=84), group B : EF <50% without`-blocker (n=120), group C : EF ≥50% with`-blocker 
(n=113), and group D : EF ≥50% without `-blocker (n=499). The changes of EF, and the percent changes of LV end-diastolic volume index (LVEDVI) 
and LV end-systolic volume index (LVESVI) were calculated at 6-8 months follow-up LVG. Clinical outcomes were assessed at long-term follow-up for 
MACE: cardiac death, non-fatal myocardial infarction, hospitalization for heart failure.
Results:  Improvement of EF was similar in group A and B, and in group C and D. There was a significantly greater decrease of both LVEDVI and 
LVESVI (reverse remodeling) in group A than group B, although there was not significantly different between group C and group D. Group A had 
significant lower incidence of MACE than group B (Figure).
Conclusion: After PCI in SAP with LV dysfunction, `-blocker therapy achieved reverse remodeling and improved the long-term outcomes. 
